Zylox-Tonbridge IPO: Trading Debut
Zylox-Tonbridge priced its IPO at HK$42.70 and closed 31% up at HK$55.85 in the Futu securities grey market. Our DCF sensitivity analysis shows...
457 Views
Shanghai Heartcare IPO: Strong Potential in Treating Strokes
Though company operates in a highly competitive market, the better performance of core products can act as growth catalysts, help capture more of...
547 Views
Zylox-Tonbridge (归创通桥) IPO Trading: Expect Strong Debut
We look at the updates of Zylox-Tonbridge IPO since our last note. Our analysis suggests a strong debut performance when it lists tomorrow.
394 Views
Acotec (先瑞达) Pre-IPO: Early Mover Advantage in Peripheral DCB
Acotec is early in the peripheral artery drug coated balloon device market with a dominant market share for above-the-knee stenosis. Having said...
383 Views
Zylox-Tonbridge IPO: DCF Valuation Offers Decent Upside to the Upper End
Our valuation offers a price per share of HK$46.42 which is 8.7% higher than the Upper end of the company’s indicative IPO price range of HK$39.8...
383 Views